Nootropics & Cognitive Compounds

What the word means · and which compounds here actually qualify

Racetam is a chemical term with a precise meaning and nootropic is a term with a formal definition that almost nothing satisfies. Both get used loosely. A buyer reading a listing frequently cannot tell what class a compound belongs to. This page sets out what each word originally meant, which of the five compounds in this category meet either standard, and what that leaves.

Specification Table

What Does Racetam Actually Name?

The suffix describes a chemical structure and nothing else, which is the first thing most listings get wrong.

A racetam is built on a 2-oxo-pyrrolidine acetamide core. That is a five-membered ring carrying an amide side chain, and nothing about the definition goes further than the shape.

Piracetam was the first, synthesised in the 1960s, and every later member of the family takes its name from that shared ring rather than from any shared mechanism.

The distinction matters. Compounds in the family act through demonstrably different routes: some modulate glutamatergic receptors, some influence membrane fluidity, and for several the mechanism is still unresolved after fifty years of work.

So racetam is a structural label in the same way that steroid is a structural label. It tells you the skeleton and it does not tell you what the compound does.

A listing describing a compound as a racetam has therefore made a chemical claim that can be checked against the structure, which is more than most category words in this market offer.

Where the word is applied to a compound lacking that ring, the claim is simply incorrect rather than vague.

That is the situation with the best-known compound in this category.

The practical test is simple. Draw the structure, look for the five-membered ring with its amide side chain, and the question answers itself in seconds.

No literature search required.

Why Is Noopept Not a Racetam?

Noopept is listed as a racetam almost everywhere and it does not have the ring.

Structurally it is a dipeptide. Specifically it is an ethyl ester built on a glycine and proline sequence, which puts it in a different chemical class altogether.

The confusion is real rather than careless. One reported metabolite is cycloprolylglycine, a cyclic dipeptide, and its ring resembles the racetam ring closely enough that the association stuck.

Its alternative name, omberacetam, makes the problem worse by attaching the suffix directly to a compound that does not qualify for it.

None of that makes the compound less interesting. It makes the naming unreliable, which matters when a researcher is reading class-level literature and applying it.

Piracetam literature is not Noopept literature, and the two compounds differ in potency by a factor frequently quoted in the hundreds, which alone should discourage treating them as equivalent.

For verification the practical consequence is that Noopept should be assessed as a small molecule with a peptide backbone, needing both mass confirmation and structural confirmation.

A certificate treating it as a simple small molecule and reporting only a mass has not distinguished it from its own hydrolysis products.

There is a further wrinkle. Noopept is an ester, so it hydrolyses, and its hydrolysis products are chemically close to the parent.

A certificate that reports only a mass cannot tell an intact ester from a partially hydrolysed sample, because the hydrolysis product differs by a small and unremarkable amount.

Chromatography separates them cleanly. Mass alone does not.

What Did Nootropic Originally Mean?

The word was coined with a definition attached, and the definition was deliberately hard to satisfy.

Corneliu Giurgea, who synthesised piracetam, set out five criteria a compound had to meet before the term applied.

It had to support memory and learning, and to hold that support up under disruptive conditions. It had to protect the brain against physical or chemical injury.

It had to increase the efficacy of cortical control mechanisms. And critically, it had to lack the pharmacology of ordinary psychotropic compounds: no sedation, no stimulation, very low toxicity.

That last criterion is the one that excludes most of what the word is now applied to, since a great many compounds marketed as nootropics are straightforwardly stimulants.

A five-criterion term applied to compounds meeting one of them has stopped being a category. It has become a marketing word.

This page uses the word because the search demand is real. It states the definition alongside it so the gap between the term and its usage is visible rather than exploited.

None of the five compounds in this category has been assessed against all five criteria in published work. That is the honest answer to whether any of them qualifies.

The definition also carried an implicit standard for evidence. Four of the five criteria describe measurable outcomes, which means a compound can be tested against them rather than merely described as meeting them.

Almost nothing in this market has been.

What Is Actually in This Category?

Five products sit here and they come from four unrelated origins, which makes the category a grouping by intended application rather than by anything chemical.

Noopept is the dipeptide described above, the only compound here with any claim to the racetam association even though the claim does not survive inspection.

P21 is peptidergic, derived from a fragment of a neurotrophic factor. It exists because the parent protein is too large to be practical as a research article.

Cerebrolysin is not a defined molecule at all. It is a porcine brain-derived peptide and amino acid mixture, so it has no sequence, no molecular weight and no CAS number, and verifying it is a manufacturing process question rather than a structural one.

Pinealon is a three-residue Khavinson bioregulator, and the brain peptides hub covers that family and its barrier argument in depth.

One small molecule. One peptide fragment. One undefined mixture, and one short bioregulator, grouped only because all four are directed at the same organ.

That organises a shop well and a literature search badly. The two should not be confused.

A researcher working here should read the compound page rather than the category page, because the category shares an intended application and no chemistry whatsoever.

Price spread across these five is wide. The bioregulator is among the cheapest articles in the catalogue and the brain-derived mixture among the more expensive, and neither price reflects how well characterised the compound is.

Reading cost as a proxy for evidence would invert the actual position here, as it does across the neuroactive range generally.

Format varies too. Two of the five are nasal sprays, which means their degradation clock started at the fill line rather than at reconstitution.

That matters here more than it would elsewhere, because a mixture with no defined structure cannot be re-assayed by a buyer to check how far it has drifted.

Ask for the fill date.

What Should Be Verified Before Ordering?

The checks differ by compound more than in any other category on this site, because the four origins need four different approaches.

For Noopept, mass confirmation and structural confirmation both. It is an ester, it hydrolyses, and the products are chemically close to the parent.

For P21, the sequence written out in full, since it is a defined peptide and a trade name on its own carries no chemical information whatsoever.

For Cerebrolysin, the manufacturing process and batch-to-batch consistency data, because there is no structure to confirm and no mass to match.

For Pinealon, the ordinary bioregulator panel: sequence, calculated mass against observed mass, counterion identity and net peptide content.

For the nasal spray formats in this category, the fill date, since solution-state material has been degrading since manufacture.

Across all of them, purity by chromatography with the method and detection wavelength stated, and the chromatogram rather than a summary figure.

Where one generic certificate template covers compounds this different, the template is doing work that analysis should be doing.

That is visible from a single certificate and it is worth checking before an order rather than after it arrives.

None of this is expensive to ask for. It is a single email, sent before the order rather than after the material has arrived and the question has become academic.

The response time is itself informative. A supplier who holds real lot data answers within a day, because the answer is already sitting in a file somewhere rather than needing to be constructed.

Silence is an answer too.

Which Compounds Make Up the Racetam Family?

The racetam family is defined by a shared ring rather than by a shared effect, and setting out the members explains why their reported activities diverge so widely.

Every member carries a 2-pyrrolidone core, the pyrrolidone nucleus that gives the class its name. Piracetam is the parent, chemically 2-oxo-1-pyrrolidine acetamide.

Aniracetam adds an anisoyl group, which makes it fat-soluble where piracetam is water-soluble, and that single change alters absorption and duration substantially.

Oxiracetam adds a hydroxyl group and pramiracetam a dipropan-2-ylaminoethyl chain, both reported as more potent than piracetam on a milligram basis.

Phenylpiracetam, sold in Russia as Phenotropil, adds a phenyl group. That addition makes it a psychostimulant as well, which is the reason it is prohibited by the World Anti-Doping Agency where the others are not.

Nefiracetam and nebracetam sit further out, with nefiracetam studied for cognitive impairment and carrying a different reported profile again.

Coluracetam takes a different route entirely, acting on high-affinity choline uptake rather than on the targets the earlier compounds are associated with.

Levetiracetam and seletracetam belong to the same chemical family and to a completely different pharmacology. Levetiracetam, marketed as Keppra, is an approved anticonvulsant acting at SV2A, and it is used in epilepsy rather than for cognition.

That is the most important disambiguation in this category. A racetam is a chemical description, not a functional one, and the presence of an approved anticonvulsant in the family should be read as evidence of that rather than as evidence of shared activity.

Noopept is frequently listed as a racetam and is not one. It is a dipeptide, structurally unrelated, though its reported effects are often described in the same terms.

What Is the Proposed Mechanism of Action?

The honest position is that the mechanism of action for the cognition-associated members is not settled, and the candidate explanations have accumulated rather than resolved.

Effects on cell membranes are the oldest proposal. Piracetam is described as altering membrane fluidity, which would affect neurotransmitter systems generally rather than any single one.

Cholinergic involvement is the most cited. Reported interaction with acetylcholine receptors, and the standard practice of pairing these compounds with a choline source, both follow from it.

That pairing is why alpha-GPC and CDP-choline appear alongside racetams so consistently. The reasoning is that increased acetylcholine turnover depletes available choline, and headaches are the effect most often attributed to running short of it.

Glutamate receptors are the other candidate. Aniracetam in particular is described as a positive allosteric modulator at AMPA receptors, and AMPA modulation connects to long-term potentiation and synaptic plasticity, which is the mechanistic route to memory enhancement.

Glutamate is the principal excitatory neurotransmitter and gamma-aminobutyric acid the principal inhibitory neurotransmitter, and GABA is where the naming confusion in this family began, since piracetam is a structural derivative of GABA that does not act on GABA receptors.

Increased cerebral blood flow is reported in some of the older literature, which is where use in stroke patients and in vascular dementia originated.

Effects on dopamine, on the dopamine transporter and on serotonin are reported for phenylpiracetam specifically, which is consistent with its stimulant character and not with the class generally.

Neuroprotection under hypoxia is the finding with the most consistent animal support across the family.

What Is the Regulatory and Evidence Position?

The regulatory position splits by jurisdiction and it is the thing most often stated incorrectly.

Piracetam is an approved medicine in a number of European countries, prescribed for cognitive impairment and for myoclonus, and it has decades of clinical use behind it there.

It is not FDA-approved in the United States. The FDA has stated that piracetam does not meet the definition of a dietary ingredient, so it cannot lawfully be sold as one of the dietary supplements either.

That leaves it in the research chemical category in the United States, which is what this catalogue supplies it as.

Phenylpiracetam is approved in Russia as Phenotropil. Aniracetam holds approvals in parts of Europe and Asia. Others hold none anywhere.

Evidence quality varies as widely as the regulatory position. Cochrane reviews of piracetam in dementia and in cognitive impairment have generally concluded the evidence does not support routine use.

Where trials do report benefit, they tend to be older, smaller and in specific clinical populations rather than in healthy adults seeking cognitive enhancement.

Reported effects on verbal fluency, cognitive function and memory come from that clinical literature rather than from studies of healthy users.

The smart drugs framing, and the associated claims about brain health, brain fog and physical performance, does not derive from those trials.

Reported side effects across the family are generally mild, with headaches, insomnia, anxiety and irritability the most common, and anxiety and depression both reported in both directions depending on the compound.

Anxiolytic and antidepressant effects are described for some members and the opposite for others, which is another consequence of a class defined chemically rather than functionally.

Dosage figures circulating for these compounds come from the European clinical literature where one exists and from forums where it does not, and bioavailability differs enough between members that a dosage for one says little about another.

Caffeine is the comparison worth making. It is the best-characterised cognition-enhancing drug available and its effects are modest, which is a useful calibration for what to expect from anything else.

Published Literature

Selected references on the original definition, on the chemical family and on two of the compounds here.

1. Giurgea C. The nootropic approach to the pharmacology of the integrative activity of the brain. Act Nerv Super (Praha). 1973;15(4):273-281. PubMed 4805348
2. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11(2):169-182. DOI: 10.1111/j.1527-3458.2005.tb00268.x
3. Ostrovskaya RU, Gudasheva TA, Zaplina AP, et al. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med. 2008;146(3):334-337. DOI: 10.1007/s10517-008-0297-x
4. Banks WA. Peptides and the blood-brain barrier. Peptides. 2015;72:16-19. DOI: 10.1016/j.peptides.2015.03.010

Frequently Asked Questions